The Effect of Graded Forced Expiration on Intraocular Pressure
The Effect of Graded Forced Expiration on Intraocular Pressure: A Study Using the Airofit Device
Uşak University
60 participants
Dec 15, 2025
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to utilize the Airofit device to systematically measure and characterize the changes in intraocular pressure across its six different levels of forced expiration. This investigation will provide crucial quantitative data on the IOP-respiratory effort relationship, enhancing our understanding of IOP dynamics during controlled respiratory stress and establishing a new, standardized paradigm for such research.
Eligibility
Inclusion Criteria6
- Aged 18 years or older.
- Willing and able to provide informed consent.
- Have a best-corrected visual acuity of 6/12 or better.
- Able to understand and follow instructions for using the Airofit device.
- Have an optic nerve cup/disc ratio not exceeding 0.5, and have a c/d difference between both eyes not exceeding 0.2.
- Did not have taken any anticholinergic medication, systemic beta-blockers, or corticosteroids within the last 3 months that could affect intraocular pressure levels.
Exclusion Criteria4
- a history of intraocular surgery,
- a history of uveitis,
- a spherical refractive error exceeding 3D,
- a history of regular topical treatment other than artificial tears
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The experiment will entail the acquisition of a total of seven intraocular pressure (IOP) measurements from each subject. * T0: Baseline (pre-intervention, resting). * T1: Immediately after 1 minute of forced expiration at Level 1. * T2: Immediately after 1 minute of forced expiration at Level 2. * T3: Immediately after 1 minute of forced expiration at Level 3. * T4: Immediately after 1 minute of forced expiration at Level 4. * T5: Immediately after 1 minute of forced expiration at Level 5. * T6: Immediately after 1 minute of forced expiration at Level 6.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07274176